Controlled, prospective, open-label trial with a total duration of 2 weeks to assess the clearance of inflammatory interleukins by different membranes in haemodialysis patients with COVID-19.

Controlled, prospective, open-label trial with a total duration of 2 weeks to assess the clearance of inflammatory interleukins by different membranes in haemodialysis patients with COVID-19.

Patients will be dialysed according to the usual dialysis schedule of three weekly sessions. The study has a duration of 8 days in order to include 4 haemodialysis sessions. The first and third haemodialysis sessions will be dialysed with PS membrane and the second and fourth sessions with PMMA membrane, both dialysers with a surface area of 1.8 m2.

Inclusion Criteria:

• Age ≥18 years .
• Patient on chronic haemodialysis admitted to the hospital with a diagnosis of infection by COVID-19.
• Signature of informed consent or legal representative.
• Estimated duration of admission greater than 8 days (4 haemodialysis sessions).
• Patient with haemodynamic stability, understood as systolic blood pressure ≥ 100 mmHg.

Exclusion Criteria:

• Refusal to sign the consent form.
• Patients who for clinical reasons are unable to follow a regular dialysis schedule of three sessions per week.
• Allergy (documented or suspected) to either of the two membranes involved in the study.
• Patient with haemodynamic instability (Mean arterial pressure < 100 mmHg).